Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study.
Martin-Blondel G, Lescure FX, Assoumou L, Charpentier C, Chapplain JM, Perpoint T, Grouteau G, Cordel H, Pialoux G, Pacanowski J, Thy M, Bauvois A, Laureillard D, Hamrouni F, Algarte-Genin M, Poissy J, Descamps D, Costagliola D; CoCliCo Study Group. Martin-Blondel G, et al. Among authors: costagliola d. BMC Infect Dis. 2022 Jun 13;22(1):540. doi: 10.1186/s12879-022-07508-x. BMC Infect Dis. 2022. PMID: 35698029 Free PMC article.
Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.
del Giudice P, Mary-Krause M, Pradier C, Grabar S, Dellamonica P, Marty P, Gastaut JA, Costagliola D, Rosenthal E; French Hospital Database on HIV Clinical Epidemiologic Group. del Giudice P, et al. Among authors: costagliola d. J Infect Dis. 2002 Nov 1;186(9):1366-70. doi: 10.1086/344325. Epub 2002 Oct 11. J Infect Dis. 2002. PMID: 12402211
Clinical and immunologic outcome in patients with human immunodeficiency virus infection, according to virologic efficacy in the year after virus undetectability, during antiretroviral therapy.
Abgrall S, Duval X, Joly V, Descamps D, Matheron S, Costagliola D; Clinical Epidemiology Group from the French Hospital Database on HIV. Abgrall S, et al. Among authors: costagliola d. Clin Infect Dis. 2003 Dec 1;37(11):1517-26. doi: 10.1086/379070. Epub 2003 Oct 29. Clin Infect Dis. 2003. PMID: 14614675
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group. Masquelier B, et al. Among authors: costagliola d. Antivir Ther. 2004 Jun;9(3):315-23. Antivir Ther. 2004. PMID: 15259894 Clinical Trial.
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
Descamps D, Chaix ML, André P, Brodard V, Cottalorda J, Deveau C, Harzic M, Ingrand D, Izopet J, Kohli E, Masquelier B, Mouajjah S, Palmer P, Pellegrin I, Plantier JC, Poggi C, Rogez S, Ruffault A, Schneider V, Signori-Schmück A, Tamalet C, Wirden M, Rouzioux C, Brun-Vezinet F, Meyer L, Costagliola D. Descamps D, et al. Among authors: costagliola d. J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):545-52. doi: 10.1097/01.qai.0000155201.51232.2e. J Acquir Immune Defic Syndr. 2005. PMID: 15793364
726 results